Familial epidermodysplasia verruciformis with intrafamilial phenotypic variability: a case series of three siblings
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20261103Keywords:
Epidermodysplasia verruciformis, Genodermatoses, Papillomavirus infections, Siblings, Skin neoplasmsAbstract
Epidermodysplasia verruciformis is a rare inherited skin disorder characterized by persistent susceptibility to selected beta human papillomavirus types. The disease usually begins in childhood and follows a slow, progressive course, with lesions increasing in number and distribution over time. Clinical severity is variable and often unpredictable, even within the same family, and the risk of later malignant transformation remains a major concern. We describe three siblings from a single family diagnosed with epidermodysplasia verruciformis to demonstrate intrafamilial variability in clinical presentation. All patients underwent detailed clinical evaluation and family history assessment. Histopathological confirmation was obtained in one sibling, while diagnosis in the remaining two was made on the basis of characteristic clinical features in a familial setting. The index patient, a 19-year-old female, developed hypopigmented and hyperpigmented lesions at six years of age, with gradual involvement of the face, trunk, limbs, and external genitalia. Her elder brother had a similar age of onset but more extensive cutaneous involvement. The younger brother presented later, at ten years of age, with fewer lesions largely confined to the limbs. None of the siblings showed clinical evidence of malignant change at evaluation.
References
Myers DJ, Rady P, Tyring SK. Epidermodysplasia verruciformis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
Lewandowsky F, Lutz W. Ein Fall einer bisher nicht beschriebenen Hauterkrankung. Arch Dermatol Syph. 1922;141:193-203.
Orth G. Epidermodysplasia verruciformis. Dermatol Clin. 1985;3(1):137-51.
Przybyszewska J, Zlotogorski A, Ramot Y. Re-evaluation of epidermodysplasia verruciformis: reconciling more than 90 years of debate. J Am Acad Dermatol. 2017;76(6):1161-75.
Boutaarourt M. Case of classic epidermodysplasia verruciformis associated with multiple β-HPV types. Oxf Med Case Reports. 2025;2025(1):omafxxx.
Ramoz N, Rueda LA, Bouadjar B. Mutations in two adjacent genes cause epidermodysplasia verruciformis. Nat Genet. 2002;32(4):579-81.
Sterling JC. Viral infections. In: Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook’s Textbook of Dermatology. 9th ed. Oxford: Wiley-Blackwell. 2016.
Moore S, Rady P, Tyring S. Acquired epidermodysplasia verruciformis: clinical presentation and treatment update. Int J Dermatol. 2022;61(11):1325-35.
Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of HPV-induced genetic cancer. Cancer Surv. 1997;31:203-14.
Lutzner MA. Epidermodysplasia verruciformis: clinical and genetic aspects. J Am Acad Dermatol. 1984;11(2):217-27.
de Jong-Tieben LM, Berkhout RJ, Smits HL. High frequency of HPV infections in epidermodysplasia verruciformis. J Invest Dermatol. 1995;104(4):651-5.
Lazarczyk M, Favre M. Role of EVER proteins in human papillomavirus infection. Microbiol Mol Biol Rev. 2008;72(2):249-60.
Jacyk WK. Epidermodysplasia verruciformis: familial variability. Clin Exp Dermatol. 2000;25(1):36-40.
Fitzpatrick TB, Eisen AZ, Wolff K, editors. Dermatology in General Medicine. 7th ed. New York: McGraw-Hill. 2008.
Rallis E, Paparizos V. Genital involvement in epidermodysplasia verruciformis. Int J Dermatol. 2007;46(3):328-30.
Weedon D. Weedon’s Skin Pathology. 4th ed. London: Elsevier. 2016.
Harwood CA, Surentheran T, McGregor JM. Human papillomavirus infection and non-melanoma skin cancer. J Pathol. 2000;191(4):377-84.
Gupta S, Malhotra AK, Verma KK. Epidermodysplasia verruciformis: therapeutic challenges. Indian J Dermatol Venereol Leprol. 2004;70(5):310-2.
Shruti S, Siraj F, Singh A, Ramesh V. Epidermodysplasia verruciformis: three case reports and a brief review. Acta Dermatovenerol Alp Pannonica Adriat. 2017;26(3):59-61.